GlaxoSmithKline boss Dame Emma Walmsley today promised a “step-change in growth” during a landmark year for the pharma giant.
Posting annual results showing a 1% drop in adjusted profits to £8.8 billion, she set out new growth targets and said the company had good monentum at the start of 2022, with multiple R&D catalysts including milestones on up to seven key late-stage pipeline assets. Glaxo will later this month reveal growth ambitions for its consumer healthcare business, which is due to be demerged in the summer.
Meanwhile, LV= revealed today that it has called off merger talks with Royal London after the former private equity target said it wanted to retain its status as an independent mutual.
